-+ 0.00%
-+ 0.00%
-+ 0.00%

LAVA Therapeutics Announces First Patient Dosed In Phase 1 Study Of Bispecific Anti-CD123 Gammabody LAVA-1266 For AML And MDS; Initial Data Expected By Year-End 2025

Benzinga·01/10/2025 13:31:02
Listen to the news
  • LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®
  • First-in-human study enrolling adult patients with CD123-expressing AML or MDS
  • Initial Phase 1 data read-out expected by year-end 2025

     

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody®, LAVA-1266, an investigational agent in development for the treatment of hematologic cancers including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).